Observational study investigating the use of levofloxacin in ICU patients;Estudio observacional sobre el uso de levofloxacino en pacientes ingresados en UCI

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 4, 2004, Pages 220-226

  Álvarez Lerma, Francisco ^a   Palomar, Mercedes ^b   Olaechea, Pedro ^c   León, Cristóbal ^d   Sánchez, Miguel ^e   Bermejo, Begoña ^f  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL DE GALDAKAO   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^f Universidad Pública de Navarra   (Spain)

Author keywords

Adverse events; Critically ill patient; ICU; Levofloxacin

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; FLUCONAZOLE; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; AGE; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; CATHETER INFECTION; CHLAMYDIA; CRITICAL ILLNESS; CYSTITIS; DIARRHEA; DRUG UTILIZATION; ENTEROBACTER; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HEART ARRHYTHMIA; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; LEGIONELLA PNEUMOPHILA; LEUKOPENIA; LIVER DYSFUNCTION; MONOTHERAPY; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA PNEUMONIAE; NAUSEA; PHLEBITIS; PRESCRIPTION; PROSPECTIVE STUDY; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; SEPSIS; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIAE;

EID: 2342533181     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059052     Document Type: Article

References (33)

1. Hooper DC. Mode of action of fluoroquinolones. Drugs 1999;58 (Suppl 2):6-10.
2. Fukada H, Hiramatsu K. Primary targets of fluoroquinolones in Streptocoecus pneumoniae. Antimicrob Agents Chemother 1999;43:410-2.
3. Schmitz FJ, Verhoef J, Fluit AC. Comparative activities of six different fluoroquinolones against 9.682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. Int J Antimicrob Agents 1999;12:311-7.
4. Montanari MP, Mingoia. M, Marchetti F, Varaldo PE. In vitro activity of levofloxacin against Gram-positive bacteria. Chemotherapy 1999;45:411-7.
5. Jones RN, Croco MA, Pfaller MA, Beach ML, Kugler KC, and SENTRY antimicrobial surveillance programs participans (The Americas). Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997). Clin Microbiol Infect 1999;5:540-6.
6. Langtry HD, Lamb HM. Levofloxacin: its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998;56:487-515.
7. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999;58 (Suppl 2): 37-42.
8. thed. Montvale: Medical Economics Company, 2000.
9. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 2001;47(Suppl 3):9-14.
10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
11. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections 1988. Am J Infect Control 1988;16:128-40.
12. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: A modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992;13:606-8.
13. Sociedad Española de Medicina Preventiva, Salud Pública e Higiene. Evolución de la Prevalencia de las Infecciones Nosocomiales en los Hospitales Españoles. Proyecto EPINE 1990-1999. Madrid: MI&C, 2001.
14. Grupo de Trabajo de Enfermedades Infecciosas de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias. Estudio Nacional de Vigilancia de Infección Nosocomial en UCI (ENVIN-UCI). Informe de la evolución de la incidencia y características de las infecciones nosocomiales en Servicios de Medicina Intensiva (1994-2001). Madrid: Jarpyo Editores, 2002.
15. Center for Diseases Control 1993. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adult. MMWR 1992;41(RR-17):1-19.
16. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998;30:397-404.
17. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Willians RR, et al. A multicenter, randomized study comparing the efficay and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
18. Frank E, Liu J, Kinasewits G, Morán GJ, Oross MP, Olson WH, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24:1292-308.
19. Shah PM, Maesen FP, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefaroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double blind study. J Antimicrob Chemother 1999;43:529-39.
20. Lasko B, Lau CY, Saint-Pierre C, Reddington JL, Martel A, Anstey RJ. Efficay and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicenter, double blind randomized staudy. The Canadian Sinusitis Study Group. J Int Med Res 1998; 26:281-91.
21. Palomar Martínez M. Datos demográficos de la población analizada. Factores de riesgo de infección nosocomial. En: Estudio Nacional de Vigilancia de Infección Nosocomial en UCI (ENVIN-UCI). Informe de la evolución de la incidencia y características de las infecciones nosocomiales adquiridas en Servicios de Medicina Intensiva (1994-2001). Madrid: Jarpyo Editores, 2002; p. 35-52.
22. Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, et al. Once-daily oral gatifloxacin versus oral levofloxacin in the treatment of uncomplicated skin and soft tissue infections: double blind, multicenter, randomized study. Antimicrob Agents Chemother 2001;45:2358-62.
23. Klimberg IW, Cox II CE, Fowler CL, King W, Kim SS, Callery-D'Amico S. A controlled trial o levofloxacin and lemofloxacin in the treatment of complicated urinary tract infection. Urology 1998;51:610-5.
24. West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, Wu SC, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter prospective, randomized, open-label study. Clin Ther 2003;25:485-506.
25. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002;28:108-21.
26. Álvarez-Lerma F, Palomar M, Olaechea P, De la Cal MA, Insausti J, Bermejo B. Estudio Nacional de Vigilancia de infección Nosocomial en Unidade de Cuidados Intensivos. Informe del año 2001. Med Intensiva 2003;27: 13-23.
27. Kays MB, Smith DW, Wack ME, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002;22:395-9.
28. Davidson R, Cavsicanti R, Brunton JL, Bast DJ, De Azavedo JC, Kibeey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
29. Segatore B, Setacci D, Perilli M, Franceschini N, De Santis A, Marchetti F, et al. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43: 428-31.
30. MacGowan AP, Wootton M, Holt A. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 1999;43:345-9.
31. Rittenhouse BE, Stinnett AA, Dulisse B, Henke CJ, Potter L, Parasuraman B, et al. Evaluating the costs of levofloxacin and ceftriaxone in inpatient adults with community-acquired pneumonia. Pharmacol Ther 1999;24: 169-79.
32. Pill MW, Sudol T. Evaluating the costs of levofloxacin and ceftriaxone in inpatient adults with community-acquired pneumonia. Pharmacol Ther 1999; 24:575-89.
33. Khan JB. Latest industry information of the safety profile of levofloxacin in the US. Chemotherapy 2001;47(Suppl. 3):32-7.